Progress in current non-viral carriers for gene delivery

Yoko Shoji-Moskowitz, Daisuke Asai, Kota Kodama, Yoshiki Katayama, Hideki Nakashima

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Since the viral vector for gene therapy has serious problems, including oncogenesity and other adverse effects, non-viral carriers have attracted a great deal of attention. However, the most critical issue of gene delivery by non-viral carriers is the low-expression efficiencies of the desired gene. In order to apply non-viral carriers for gene therapy in practical clinical usage, the improvement of transfection efficiency is a prerequisite. We will summarize the current progress of non-viral delivery systems for gene therapy. Especially, we will address the applications of cationic lipids (lipoplex) and cationic polymers (polyplex) in vivo. Furthermore, there have been reported a disease-site-specific delivery system which responds to highly activated cellular signals, which is called a drug delivery system based on responses cellular signal (D-RECS). We will also introduce the current progress of D-RECS gene delivery which is activated by HIV protease in only HIV-infected cells.

Original languageEnglish
Pages (from-to)81-97
Number of pages17
JournalFrontiers in Medicinal Chemistry
Volume5
Issue number1
Publication statusPublished - Jan 1 2010

Fingerprint

Gene therapy
Genetic Therapy
Genes
HIV Protease
Viral Genes
Drug Delivery Systems
Transfection
Polymers
HIV
Lipids

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery
  • Organic Chemistry

Cite this

Shoji-Moskowitz, Y., Asai, D., Kodama, K., Katayama, Y., & Nakashima, H. (2010). Progress in current non-viral carriers for gene delivery. Frontiers in Medicinal Chemistry, 5(1), 81-97.

Progress in current non-viral carriers for gene delivery. / Shoji-Moskowitz, Yoko; Asai, Daisuke; Kodama, Kota; Katayama, Yoshiki; Nakashima, Hideki.

In: Frontiers in Medicinal Chemistry, Vol. 5, No. 1, 01.01.2010, p. 81-97.

Research output: Contribution to journalArticle

Shoji-Moskowitz, Y, Asai, D, Kodama, K, Katayama, Y & Nakashima, H 2010, 'Progress in current non-viral carriers for gene delivery', Frontiers in Medicinal Chemistry, vol. 5, no. 1, pp. 81-97.
Shoji-Moskowitz Y, Asai D, Kodama K, Katayama Y, Nakashima H. Progress in current non-viral carriers for gene delivery. Frontiers in Medicinal Chemistry. 2010 Jan 1;5(1):81-97.
Shoji-Moskowitz, Yoko ; Asai, Daisuke ; Kodama, Kota ; Katayama, Yoshiki ; Nakashima, Hideki. / Progress in current non-viral carriers for gene delivery. In: Frontiers in Medicinal Chemistry. 2010 ; Vol. 5, No. 1. pp. 81-97.
@article{3d999ed074a746b78ebb8976deaeb530,
title = "Progress in current non-viral carriers for gene delivery",
abstract = "Since the viral vector for gene therapy has serious problems, including oncogenesity and other adverse effects, non-viral carriers have attracted a great deal of attention. However, the most critical issue of gene delivery by non-viral carriers is the low-expression efficiencies of the desired gene. In order to apply non-viral carriers for gene therapy in practical clinical usage, the improvement of transfection efficiency is a prerequisite. We will summarize the current progress of non-viral delivery systems for gene therapy. Especially, we will address the applications of cationic lipids (lipoplex) and cationic polymers (polyplex) in vivo. Furthermore, there have been reported a disease-site-specific delivery system which responds to highly activated cellular signals, which is called a drug delivery system based on responses cellular signal (D-RECS). We will also introduce the current progress of D-RECS gene delivery which is activated by HIV protease in only HIV-infected cells.",
author = "Yoko Shoji-Moskowitz and Daisuke Asai and Kota Kodama and Yoshiki Katayama and Hideki Nakashima",
year = "2010",
month = "1",
day = "1",
language = "English",
volume = "5",
pages = "81--97",
journal = "Frontiers in Drug Design and Discovery",
issn = "1574-2042",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Progress in current non-viral carriers for gene delivery

AU - Shoji-Moskowitz, Yoko

AU - Asai, Daisuke

AU - Kodama, Kota

AU - Katayama, Yoshiki

AU - Nakashima, Hideki

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Since the viral vector for gene therapy has serious problems, including oncogenesity and other adverse effects, non-viral carriers have attracted a great deal of attention. However, the most critical issue of gene delivery by non-viral carriers is the low-expression efficiencies of the desired gene. In order to apply non-viral carriers for gene therapy in practical clinical usage, the improvement of transfection efficiency is a prerequisite. We will summarize the current progress of non-viral delivery systems for gene therapy. Especially, we will address the applications of cationic lipids (lipoplex) and cationic polymers (polyplex) in vivo. Furthermore, there have been reported a disease-site-specific delivery system which responds to highly activated cellular signals, which is called a drug delivery system based on responses cellular signal (D-RECS). We will also introduce the current progress of D-RECS gene delivery which is activated by HIV protease in only HIV-infected cells.

AB - Since the viral vector for gene therapy has serious problems, including oncogenesity and other adverse effects, non-viral carriers have attracted a great deal of attention. However, the most critical issue of gene delivery by non-viral carriers is the low-expression efficiencies of the desired gene. In order to apply non-viral carriers for gene therapy in practical clinical usage, the improvement of transfection efficiency is a prerequisite. We will summarize the current progress of non-viral delivery systems for gene therapy. Especially, we will address the applications of cationic lipids (lipoplex) and cationic polymers (polyplex) in vivo. Furthermore, there have been reported a disease-site-specific delivery system which responds to highly activated cellular signals, which is called a drug delivery system based on responses cellular signal (D-RECS). We will also introduce the current progress of D-RECS gene delivery which is activated by HIV protease in only HIV-infected cells.

UR - http://www.scopus.com/inward/record.url?scp=84880161835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880161835&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 81

EP - 97

JO - Frontiers in Drug Design and Discovery

JF - Frontiers in Drug Design and Discovery

SN - 1574-2042

IS - 1

ER -